March 7, 2023, 16:45 - 17:15
Numerous studies have investigated the role of circulating proteins in COVID-19 disease using different proteomics platforms. In this talk, several studies using Olink technology will be presented, e.g. on whether there are differences between e.g. bacterial sepsis and COVID-19. In addition, to identify the most robust protein markers for disease and underlying metabolic pathways relevant in different conditions, Olink proteomic profiles from two newly recruited COVID-19 studies were combined with those from three previously published COVID-19 studies. Case/control analysis revealed thirteen proteins (CCL16, CCL7, CXCL10, CCL8, LGALS9, CXCL11, IL1RN, CCL2, CD274, IL6, IL18, MERTK, IFNg, and IL18R1) that were differentially expressed in COVID-19 patients in all five studies. Pathway analysis revealed consistent trends in pathways related to cytokine-cytokine interaction, IL18 signaling, fluid shear stress, and rheumatoid arthritis in all studies. In addition, IgG autoantibody profiles were collected to further explore the impact of the immune response against endogenous proteins.